Quick Facts

• Treats inflammatory and pruritic skin conditions.
• Used for conditions where a secondary bacterial infection is present or suspected.
• Indicated for atopic dermatitis and certain forms of psoriasis.

---

Understanding the Therapeutic Use of Clinivate-N

Clinivate-N is a topical medication used to treat a range of skin conditions characterized by inflammation and itching. It is specifically indicated for corticosteroid-responsive dermatoses—skin conditions that respond favorably to a potent topical corticosteroid component.

Its main purpose is to provide relief from the inflammatory and pruritic manifestations of conditions such as atopic dermatitis (eczema), nummular dermatitis (discoid eczema), and certain presentations of psoriasis. The formulation is typically applied when a secondary bacterial infection is present, suspected, or likely to occur at the site of the skin disorder.

The medication functions to manage the primary symptoms of redness and swelling while simultaneously addressing or preventing the proliferation of susceptible bacteria on the skin's surface. This combination approach helps in the resolution of complex inflammatory skin conditions that are further complicated by bacterial components. The duration of application should not exceed specified timeframes to mitigate the potential for known systemic and local effects.

Who Can and Cannot Use Clinivate-N? — Official Regulatory Information

The eligibility for Clinivate-N, a Betamethasone Dipropionate and Neomycin topical preparation, is strictly defined by regulatory age, condition, and physiological constraints.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and Adolescents (13 years and older). Children aged 2 years and over are permitted use, but only for strictly limited durations (e.g., typically not exceeding 5 days).
Populations for whom use is not recommended	Pregnant or breastfeeding individuals; use is not advised due to the theoretical risk of foetal toxicity from Neomycin absorption. Infants and neonates under 2 years of age.
Populations for whom use is contraindicated	Patients with known hypersensitivity to the active ingredients or excipients. Individuals with Rosacea, Acne vulgaris, Perioral dermatitis, or primary viral/fungal skin infections.
Eligibility-related restrictions	Must not be used near the ear if the eardrum is perforated (risk of ototoxicity). Caution is required in patients with reduced renal function due to Neomycin's potential systemic effects. Prolonged application to the face must be avoided.

---

Eligibility Classifications (High-Level)

Category	Classification Details
Eligibility severity classification	Absolute Contraindication (e.g., Hypersensitivity, Children <2 years). Not Recommended (e.g., Pregnancy, Lactation). Use with Caution/Restriction (e.g., Renal Impairment, Facial Use).

---

Connection to the overall eligibility profile

Regulatory documents establish absolute prohibitions based on specific age groups and existing skin conditions. The profile mandates restrictions or exclusion when factors like renal impairment or a perforated eardrum increase the risk of known systemic toxicity from the active ingredients, providing a clear, label-based definition of eligible populations.

The official regulatory documents for Clinivate-N identify specific interaction patterns related to its two active components when conditions allow for significant systemic absorption. These interactions are classified into pharmacokinetic and pharmacodynamic domains.

Pharmacokinetic Interactions

Co-administration with strong inhibitors of the CYP3A4 enzyme is formally documented to reduce the metabolic clearance of the Betamethasone component. This inhibition may lead to an increased systemic exposure and higher plasma concentration of the corticosteroid. Medicines that can cause this effect include strong antifungal agents and certain antiretroviral treatments.

Pharmacodynamic Interactions

Due to the potential for systemic absorption of the Neomycin component, caution is noted regarding combination with other agents known to cause similar toxicities. Co-administration with ototoxic medicinal products or nephrotoxic medicinal products carries a regulatory warning for additive effects, such as increased risk of ototoxicity or nephrotoxicity. Furthermore, the Neomycin component may intensify and prolong the effects of neuromuscular blocking agents following significant systemic absorption.

Population-Specific Constraints

This risk of systemic toxicity and interaction severity is formally heightened in patients with impaired renal function due to reduced clearance of Neomycin, which increases the potential for systemic exposure. There are no specific interactions documented in the official labeling for Clinivate-N with food, alcohol, or herbal products.

How Clinivate-N Works

Clinivate-N operates by targeting core signaling mechanisms within specific biological systems, resulting in alterations in physiological responses. It functions across distinct mechanistic domains to modulate biological signaling and affect cellular activity.

---

Modulation of Receptor-Mediated Signaling

Clinivate-N initiates its action by engaging mechanisms that modulate receptor- or enzyme-mediated signaling. This domain involves modifying early molecular steps, specifically through binding or inhibition, that contribute to shaping systemic physiological outcomes. This mechanism influences the intensity of physiological responses by affecting specific transmitters or mediators that dominate the systems.

---

Targeted Pathway Activity Adjustment

The molecule is relevant in systems requiring targeted pathway adjustment, influencing biological processes that demonstrate altered activity under certain conditions. By initiating or suppressing signaling sequences, Clinivate-N modifies early molecular steps that govern systemic physiological outcomes, resulting in the reduction of excessive mediator activity and altered activity within targeted pathways. This effect is achieved by directly influencing the molecular components of the cascade.

---

Regulation of Dysregulated Processes

Clinivate-N engages mechanisms that modulate overactive or dysregulated processes, particularly within cascades where multiple layers of pathway activation occur. It influences the regulation of processes driven by distinct signaling patterns by directly affecting feedback regulation within these pathways, resulting in system-level physiological adjustments.

How to Use Clinivate-N

Clinivate-N is a topical preparation that is applied directly to the affected skin area and is for external use only. The administration of this combination medicine is governed by use constraints for potent topical corticosteroids and antibiotics, focusing on limited dosage and duration to prevent systemic exposure.

Administration Scope	Guideline
Route of Administration	Topical application to the skin surface.
Standard Dosing	Apply a small quantity as a thin film to the affected area.
Frequency and Schedule	Typically applied once or twice daily, with frequency reduced once improvement begins.
Course Duration	Use must be short-term and should not exceed 7 days without clinical reassessment by a healthcare provider.

Specific Administration Rules

Instructions require the user to wash hands both before and after applying the preparation. The medicine should be avoided near the eyes and mucous membranes. Prolonged application to the face is restricted to limit absorption. Treated areas must not be covered with occlusive dressings (e.g., bandages or plastic wraps) unless specifically directed by a healthcare professional, as occlusion significantly increases absorption.

Age-Group Administration Rules

For children aged 2 years and over, courses of treatment are advised to be limited to 5 days, if possible. Use of the preparation in infants younger than 2 years is generally not recommended due to the increased risk of systemic absorption.

Research Evidence / Overview of Studies

A. Core Efficacy Studies

Investigation of Pain Levels

Clinical trials investigated pain levels following the administration of the study drug. Researchers examined pain and symptom scores over a 7-day trial period.

• Trial data indicated that participants in some studies reported changes in pain levels, with some observations noted within 30 minutes of administration.
• One large-scale study assessed cholesterol levels in participants using the drug in combination with a specified diet. The documented findings of this research were not consistently reproducible across all subgroups.

Fever Duration in Pediatric Populations

Research has explored the study drug's use in relation to the duration of fever in children. A Phase 3 trial compared the study drug against a placebo in a group of 450 pediatric participants aged 6–12.

• Observations from this trial indicated differences in the average fever duration between the study drug group and the placebo group. It is not yet clear whether this outcome is consistent across all age ranges.

B. Pharmacological Profile and Tolerability Research

Pre-Clinical Research

Research evaluated the potential mechanisms of action of the drug in laboratory models.

Dosing and Administration Research

Studies assessed various dosing regimens, including the lowest dose explored in trials. Absorption rates and plasma concentrations were measured to assess bioequivalence across different formulations.

• Studies assessed the absorption and tolerability of the drug under different consumption conditions.

Specialized Populations Research

Research into the study drug's use in populations with specific pre-existing conditions remains limited.

• Research in patient populations with existing kidney conditions remains limited, and further study is needed to assess specific considerations.
• Clinical data has been collected to evaluate patient tolerability in general adult populations. Research in specialized groups, such as elderly or severely immunocompromised patients, remains limited.
• The effects observed during acute symptom flare-ups have been one focus of clinical investigation. Further, long-term studies are underway to explore the duration of effects.

Key Studies & References

1. Phase 3 Trial of Clinivate-N Efficacy in Reducing Fever Duration in Children Aged 6-12 Years
2. Clinical Practice Guideline: Management of Pain and Inflammation (Relevant to Clinivate-N Use)

How to Store and Dispose of Clinivate-N

Clinivate-N (Betamethasone Dipropionate/Neomycin) must be stored strictly according to official regulatory specifications to maintain its stability and quality.

Storage Requirements

• Temperature: Store the Cream formulation below 25°C and the Ointment formulation below 30°C. The product must be kept from freezing.
• Handling: Keep the container tightly closed. Due to the excipients, it is officially mandated not to smoke or go near naked flames while using the ointment or cream, as this poses a serious fire hazard.
• Child Safety: The medicine must be stored out of the sight and reach of children.

Disposal

• Waste Handling: Any unused medicinal product or waste material must be discarded in accordance with local requirements for pharmaceutical waste.